- Home
- FRAF vs ANVS Comparison
FRAF vs ANVS Comparison
Compare FRAF & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRAF | ANVS |
|---|---|---|
| Founded | 1906 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.0M | 76.6M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FRAF | ANVS |
|---|---|---|
| Price | $63.04 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 21.2K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | ★ 88.84 | 39.39 |
| EPS | ★ 2.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.44 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $21.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.47 | $1.04 |
| 52 Week High | $65.41 | $5.50 |
Technical Indicators
Market Signals| Indicator | FRAF | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.69 | 28.22 |
| Support Level | $60.34 | N/A |
| Resistance Level | $64.43 | $2.02 |
| Average True Range (ATR) | 1.50 | 0.10 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 64.29 | 14.78 |
Price Performance
Historical ComparisonAbout FRAF Franklin Financial Services Corporation
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.